• Provision of signed and dated written ICF prior to any mandatory and non-mandatory study-specific procedures, sampling and analyses.

• Participant must be ≥18 years (≥ 19 years of age in South Korea) at the time of signing the informed consent. All genders are permitted.

• Histologically or cytologically confirmed locally advanced or metastatic NSCLC which is not amenable to curative therapy.

• Must have at least one documented sensitising EGFR mutation: exon19 deletion, L858R mutation, and/or T790M.

• Documented radiologic progression on first- or second-line treatment with osimertinib as the most recent anti-cancer therapy.

• Mandatory provision of FFPE tumour tissue.

• MET overexpression and/or amplification in tumour specimen collected following progression on prior osimertinib treatment.

• Measurable disease as defined by RECIST 1.1.

• Adequate haematological, liver, renal and cardiac functions, and coagulation parameters.

• ECOG performance status of 0 or 1.